股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * ST 四 环 公 告 编 号 ： 临 - 2 0 2 5 - 5 2 号 江苏四环生物股份有限公司 关于全资子公司减资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次减资的基本情况 根据管理和发展的实际需要，江苏四环生物股份有限公司（以下简称"公司"） 的全资子公司江苏晨薇生态园科技有限公司（以下简称"晨薇生态园")拟对注 册资本减资 15,000 万元。本次减资后，晨薇生态园注册资本由 40,000 万元减至 25,000 万元，仍为公司的全资子公司。 公司于 2025 年 8 月 25 日召开了第十届董事会第十六次会议，审议通过了《关 于全资子公司江苏晨薇生态园科技有限公司减资的议案》。根据《深圳证券交易 所股票上市规则》、《公司章程》等有关规定，本次交易不构成关联交易，亦不 构成重大资产重组，本次减资事项无需提交公司股东大会审议。 二、本次减资主体的基本情况 公司名称：江苏晨薇生态园科技有限公司 类型：有限责任公司（非自然人投资或控股的法人投资） 法定代表人：冯靖 注册资 ...

江苏四环生物股份有限公司 2025 年半年度报告全文 江苏四环生物股份有限公司 2025 年半年度报告 【2025 年 8 月】 所有董事均已出席了审议本次半年报的董事会会议。 本报告如涉及未来发展计划等前瞻性陈述，该计划不构成公司对投资者 的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当 理解计划、预测与承诺之间的差异。 公司在经营管理中可能面临的风险及应对措施已在本报告"第三节 管理 层讨论与分析"之"十、公司面临的风险和应对措施"部分予以描述，敬请 投资者关注相关内容。 公司 2024 年度经审计的财务数据触及《深圳证券交易所股票上市规则》 第 9.3.1 条之"（一）最近一个会计年度经审计的利润总额、净利润、扣除 非经常性损益后的净利润三者孰低为负值，且扣除后的营业收入低于 3 亿元" 规定的对股票交易实施退市风险警示的情形，公司股票交易被实施退市风险 警示(股票简称前冠以"*ST"字样)。敬请广大投资者注意风险，谨慎投资。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 1 江苏四环生物股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 837344 | 三元基因 | 30.72 | -3.64% | 2.94万 | 9044.53万 | | 002773 | 康弘药业 | 42.26 | -3.38% | 11.33万 | 4.81亿 | | 430047 | 诺思兰德 | 28.23 | -3.16% | 8.74万 | 2.50亿 | | 833575 | 康乐卫士 | 17.80 | -2.57% | 5.20万 | 9287.66万 | | 000534 | 万泽股份 | 16.90 | -1.74% | 18.96万 | 3.20 Z | | 300841 | 康华生物 | 84.77 | -1.70% | 4.19万 | 3.55亿 | | 600211 | 西藏药业 | 46.04 | -1.62% | 9.87万 | 4.54亿 | | 688163 | 赛伦生物 | 25.23 | -1.60% | 1.79万 | 4519.15万 | | 688293 | 奥 ...

Core Points - Jiangsu Sihuan Biological Co., Ltd. has changed its registered address and revised its Articles of Association, which were approved by the board and shareholders [1][2] - The company has completed the necessary business registration changes and obtained a new business license [1] - The new registered information includes the company name, unified social credit code, type, legal representative, registered capital, establishment date, and new address [1] Company Information - Company Name: Jiangsu Sihuan Biological Co., Ltd. [1] - Unified Social Credit Code: 913202001381477183 [1] - Type: Joint-stock company (listed) [1] - Legal Representative: Qiu Weibing [1] - Registered Capital: 1,029.556222 million RMB [1] - Establishment Date: May 18, 1992 [1] - New Address: 41st Floor, No. 2 Binhai East Road, Jiangyin City [1] Business Scope - The company manufactures large-volume injectables, small-volume injectables (including anti-tumor drugs), tablets (including anti-tumor drugs), hard capsules, syrups, oral solutions, alcohol preparations, raw materials, and traditional Chinese medicine extracts [1] - It also engages in the manufacturing of pharmaceutical intermediates (excluding chemical hazardous products), medical information consulting, technology transfer services, and various manufacturing and sales activities [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日召开 了第十届董事会第十三次会议，审议通过了《关于变更注册地址并修订 <公司章> 程>的议案》（公告编号：临-2025-38 号），上述议案已经 2025 年第三次临时 股东会审议通过（公告编号：临-2025-46 号）。 近日，公司已完成了相关工商变更登记和章程备案手续，并取得了新的《营 业执照》，公司变更后的注册信息如下： 公司名称：江苏四环生物股份有限公司 统一社会信用代码：913202001381477183 股 票 代 码 ： 000518 股 票 简 称 ： *ST 四 环 公 告 编 号 ： 临 -2025-49 号 江苏四环生物股份有限公司 关于完成工商变更登记备案并换发营业执照 暨变更办公地址的公告 江苏四环生物股份有限公司 类型：股份有限公司（上市） 法定代表人：邱为碧 注册资本：102,955.6222 万人民币 成立日期：1992 年 5 月 18 日 住所：江阴市滨江东路 2 号 41 楼 05、06 座 经营范 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * S T 四 环 公 告 编 号 ： 临 - 2025 - 4 9 号 江苏四环生物股份有限公司 关于完成工商变更登记备案并换发营业执照 统一社会信用代码：913202001381477183 类型：股份有限公司（上市） 法定代表人：邱为碧 注册资本：102,955.6222 万人民币 成立日期：1992 年 5 月 18 日 住所：江阴市滨江东路 2 号 41 楼 05、06 座 暨变更办公地址的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日召开 了第十届董事会第十三次会议，审议通过了《关于变更注册地址并修订<公司章 程>的议案》（公告编号：临-2025-38 号），上述议案已经 2025 年第三次临时 股东会审议通过（公告编号：临-2025-46 号）。 近日，公司已完成了相关工商变更登记和章程备案手续，并取得了新的《营 业执照》，公司变更后的注册信息如下： 公司名称：江苏四环生物股份有限公司 股 票 代 码 ...

Core Viewpoint - Jiangsu Sihuan Bioengineering Co., Ltd. (referred to as "Sihuan Bio" or "*ST Sihuan") expects to increase revenue without profit in the first half of 2025, projecting revenue of approximately 180 million to 190 million yuan, a year-on-year increase of 70.12% to 79.57%, while net profit attributable to shareholders is expected to be a loss of 9 million to 13 million yuan, widening from a loss of 11.0581 million yuan in the same period last year [1][2]. Group 1: Financial Performance - Sihuan Bio's revenue is projected to grow significantly due to bulk sales of seedlings by its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd., despite a slight decline in revenue from its main subsidiary, Beijing Sihuan Bio-Pharmaceutical Co., Ltd. [2] - The company has reported continuous losses for four consecutive years, with revenues of 351 million yuan, 270 million yuan, 235 million yuan, and 204 million yuan from 2021 to 2024, and corresponding losses of 34.79 million yuan, 48.79 million yuan, 75.27 million yuan, and 110 million yuan [6][8]. Group 2: Legal and Regulatory Issues - Sihuan Bio is facing ongoing financial burdens due to securities false statement liability disputes, with 188 investors filing lawsuits against the company, totaling 41.2075 million yuan in claims [3]. - The company has been penalized by the China Securities Regulatory Commission (CSRC) for false disclosures regarding its actual controller, leading to administrative penalties and market bans for the former actual controller, Lu Keping [4][5]. Group 3: Market Challenges - The company is experiencing significant sales pressure due to intensified competition and price reductions in the pharmaceutical industry, particularly in the context of centralized drug procurement [7][8]. - Despite an increase in research and development (R&D) personnel and investment, the company’s core pharmaceutical business has not shown substantial improvement, relying instead on non-core business revenue for short-term gains [8].

Core Viewpoint - The company, Jiangsu Sihuan Biological Co., Ltd., anticipates a significant increase in revenue for the first half of 2025, despite reporting a net loss attributed to various operational challenges [1][2]. Financial Performance Summary - Expected operating revenue for the period is projected to be approximately 105.81 million yuan, representing a year-on-year growth of 70.12% to 79.57% [1]. - The net loss attributable to shareholders is estimated to be between 9 million to 13 million yuan, compared to a loss of 11.06 million yuan in the same period last year, indicating a decrease of 17.56% to 18.61% [1]. - The net loss after deducting non-recurring gains and losses is expected to be between 10 million to 14 million yuan, a decline of 42.75% to 1.96% compared to a loss of 9.81 million yuan last year [1]. - Basic earnings per share are projected to be between -0.0126 yuan and -0.0087 yuan, compared to -0.0107 yuan per share in the previous year [1]. Reasons for Performance Changes - The primary reason for the company's losses is a slight decline in revenue from its subsidiary, Beijing Sihuan Biological Pharmaceutical Co., Ltd., along with increased management expenses due to legal fees related to a securities fraud case [2]. - Conversely, the increase in operating revenue is attributed to a strategic cooperation agreement between its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd., and Jiangyin Xinganfa Trading Co., Ltd., leading to a substantial rise in sales of seedlings [2]. Other Relevant Information - The performance forecast is based on preliminary estimates from the company's finance department, with final figures to be confirmed in the official half-year report for 2025 [2].

Core Viewpoint - *ST SiHuan (000518) expects a significant increase in revenue for the first half of 2025, while still projecting a net loss for the same period [1] Revenue Forecast - The company anticipates revenue between 180 million to 190 million yuan for the period from January 1, 2025, to June 30, 2025, representing a year-on-year growth of 70.12% to 79.57% [1] Profitability Outlook - The expected net loss attributable to shareholders is projected to be between -13 million to -9 million yuan, reflecting a year-on-year change of -17.56% to 18.61% [1] - The net loss after excluding non-recurring gains and losses is forecasted to be between -14 million to -10 million yuan, indicating a year-on-year decline of 42.75% to -1.96% [1] Earnings Per Share - The basic earnings per share is estimated to be between -0.0126 yuan to -0.0087 yuan [1]

[Jiangsu Sihuan Bioengineering Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=%E6%B1%9F%E8%8B%8F%E5%9B%9B%E7%8E%AF%E7%94%9F%E7%89%A9%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8%202025%20%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) [Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company forecasts H1 2025 operating revenue between **180 million and 190 million yuan**, a **70.12% to 79.57%** increase, but expects a net loss attributable to shareholders ranging from **9 million to 13 million yuan** Performance Forecast for H1 2025 | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Operating Revenue** | 180 million yuan to 190 million yuan | 105.8084 million yuan | | | Year-on-year growth: 70.12% to 79.57% | | | **Net Profit Attributable to Shareholders of Listed Company** | Loss: -13 million yuan to -9 million yuan | -11.0581 million yuan | | | Year-on-year change: -17.56% to 18.61% | | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Loss: -14 million yuan to -10 million yuan | -9.8074 million yuan | | | Year-on-year decrease: -42.75% to -1.96% | | | **Basic Earnings Per Share** | -0.0126 yuan/share to -0.0087 yuan/share | -0.0107 yuan/share | [Pre-Audit Status of Performance Forecast](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E9%A2%84%E5%AE%A1%E8%AE%A1%E6%83%85%E5%86%B5) This performance forecast has not been audited by a certified public accountant, and its accuracy awaits final audit confirmation - This performance forecast has not been audited by a certified public accountant[2](index=2&type=chunk) [Analysis of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0) During the reporting period, the company experienced revenue growth without profit increase, primarily due to subsidiary's nursery stock sales and increased losses from the core pharmaceutical subsidiary, compounded by rising management fees from litigation expenses - Significant growth in operating revenue is primarily due to a strategic cooperation agreement between wholly-owned subsidiary Jiangsu Chenwei Ecological Park Technology Co., Ltd. and Jiangyin Xingangfa Trading Co., Ltd. for bulk sales of nursery stock[3](index=3&type=chunk) - The main reasons for the performance loss are a decrease in main business revenue and increased losses from the controlling subsidiary Beijing Sihuan Bio-Pharmaceutical Co., Ltd., and increased management expenses and losses for the parent company due to legal fees for securities false representation lawsuits[3](index=3&type=chunk) [Other Relevant Information and Risk Warning](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company states that this performance forecast is a preliminary estimate, with final accurate financial data subject to the 2025 semi-annual report, advising investors of potential investment risks - This performance forecast data is a preliminary estimate by the company's finance department, with specific data subject to the company's 2025 semi-annual report, reminding investors to be aware of investment risks[4](index=4&type=chunk)[5](index=5&type=chunk)